Koers Basilea Pharmaceutica AG Xetra
Aandelen
PK5
CH0011432447
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 182 mln. 202 mln. 188 mln. | Omzet 2025 * | 198 mln. 219 mln. 204 mln. | Marktkapitalisatie | 471 mln. 522 mln. 486 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 26 mln. 28,77 mln. 26,81 mln. | Nettowinst (verlies) 2025 * | 29 mln. 32,09 mln. 29,9 mln. | EV/omzet 2024 * | 2,9 x |
Nettoschuld 2024 * | 56,76 mln. 62,82 mln. 58,53 mln. | Nettoschuld 2025 * | 12,51 mln. 13,84 mln. 12,9 mln. | EV/omzet 2025 * | 2,45 x |
K/w-verhouding 2024 * |
18,4
x | K/w-verhouding 2025 * |
16,8
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,61% |
Recentste transcriptie over Basilea Pharmaceutica AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 01-09-14 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 01-01-09 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 01-05-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 27-04-17 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 01-01-22 |
Director/Board Member | 69 | 09-04-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,56% | 45,51 mld. | |
-9,70% | 38,52 mld. | |
+38,08% | 38,13 mld. | |
+28,02% | 30,74 mld. | |
-8,64% | 26,03 mld. | |
+11,83% | 25,92 mld. | |
+45,25% | 14,13 mld. | |
+33,49% | 12,73 mld. | |
-7,63% | 11,29 mld. |